UCB’S IMPRESSIVE FULL DECK (ADD; 15% UPSIDE)
27/11/20 -"After being range-bound for the most part of 2019, UCB (Add, Belgium) gained momentum in October 2019 when the company made an acquisition in the fast-growing (c.10% p.a.) myasthenia gravis/MG space ..."
Pages
56
Language
English
Published on
27/11/20
You may also be interested by these reports :
21/08/26
The H1 profitability surpassed consensus, though sales matched expectations. The Branded segment was the sole driver of sales growth in H1, though ...
21/08/26
Siegfried delivered a strong set of results in 1H26. Net sales grew by +2.2% YoY (+4.8% in LC), largely supported by the additional revenues ...
21/08/26
Moderna’s mRNA cancer vaccine combined with Merck’s Keytruda does look like a game changer for the wider pharma industry. It looks like a decisive ...
20/08/26
Moderna’s late-stage skin cancer vaccine success nearly tripled its share price yesterday and opened a new realm within cancer treatment. Other ...